S-1/A: Tivic Health Systems Announces Offering of Common Stock and Warrants, Proceeds to Fund Operations and Expansion

Health tech company Tivic Health Systems, Inc. is offering up to 6,481,481 shares of common stock and warrants to raise capital for working capital and general corporate purposes.

Summary

• Tivic Health Systems, Inc. is offering up to 6,481,481 shares of common stock and common warrants, with the potential for pre-funded warrants, in a best efforts offering.
• The offering price is set at $1.08 per share and common warrant, with pre-funded warrants priced at the same amount minus $0.001.
• The company aims to raise approximately $6.4 million in net proceeds, after deducting placement agent fees and estimated offering expenses.
• The funds are intended for working capital, general corporate purposes, research and development, and potential future acquisitions.
• Tivic Health is focused on bioelectronic medicine and currently markets ClearUP Sinus Pain Relief, an FDA-approved device for sinus pain and congestion.
• The company is also developing a non-invasive vagus nerve stimulation platform.
• Tivic Health faces competition from established pharmaceutical and non-pharmaceutical treatments for sinus pain and congestion.
• The company has a limited operating history and has incurred net losses since its inception, with a net loss of $8.2 million in 2023.
• Tivic Health's independent registered public accounting firm has raised substantial doubt about the company's ability to continue as a going concern.
• The company is taking measures to reduce operating expenses and is exploring strategic acquisitions to enhance growth.

Sentiment

Score: 3

Explanation: The document presents a mixed picture of Tivic Health. While the company has innovative products and is operating in a growing market, it faces significant financial challenges, including a history of losses, negative cash flow, and substantial doubt about its ability to continue as a going concern. The need for additional capital and the uncertainty surrounding its ability to achieve profitability contribute to a cautious outlook.

Positives

• Tivic Health has secured FDA and CE Mark approvals for its ClearUP Sinus Pain Relief product.
• The company has a growing intellectual property portfolio with six issued U.S. patents and 21 pending.
• Tivic Health has established distribution agreements with major healthcare distributors.
• The company has successfully reduced production costs and improved gross margins in 2023.
• Tivic Health is expanding its product portfolio with a focus on vagus nerve stimulation.
• The company has been recognized for its innovation in the bioelectronic medicine field.
• Tivic Health has launched a B2B portal and partnered with InStep Health to increase physician and healthcare provider engagement.

Negatives

• Tivic Health has a limited operating history and has incurred net losses since inception.
• The company's independent registered public accounting firm has raised substantial doubt about its ability to continue as a going concern.
• Tivic Health faces competition from larger, well-established companies in the sinus, cold, and allergy market.
• The company's revenue and income-producing potential is unproven.
• The clinical and consumer acceptance of Tivic Health's core technology is unproven.
• The company is reliant on third-party suppliers and manufacturers.
• Tivic Health has identified a material weakness in its internal control over financial reporting.
• The company's operating results may be volatile and are not a reliable indicator of future performance.

Risks

• Tivic Health's cash and financial resources may be insufficient to meet its anticipated needs for the next twelve months.
• The company may not achieve or maintain profitability in the future.
• Additional capital may be needed, which could dilute the ownership interest of investors.
• The market acceptance of bioelectronic treatments is immature.
• The company faces risks associated with cybersecurity breaches and disruptions.
• Supply chain disruptions and inflation could adversely affect the company's operations.
• The loss of key personnel or an inability to attract and retain skilled employees could impair growth.
• Changes in the regulatory landscape could impact the company's business model and require additional clearances or approvals.
• The company's reliance on vendors in foreign countries, including China, subjects it to risks related to foreign laws and regulations.
• Tivic Health's intellectual property protection methods may not be adequate or could be costly to enforce.
• The company may face risks of claims for intellectual property infringement.
• The market price of Tivic Health's common stock has fluctuated significantly and may continue to do so.
• There is no public market for the Pre-Funded Warrants or Common Warrants being offered.
• The company's management will have broad discretion over the use of the net proceeds from the offering.

Future Outlook

The company expects operating expenses to increase as it advances its vagus nerve platform, develops new product candidates, seeks regulatory approvals, and commercializes new products. Tivic Health plans to increase research and development investments in its vagus nerve platform and clinical applications. The company anticipates needing additional capital to fund operations and execute its business plan.

Industry Context

Tivic Health operates in the bioelectronic medicine market, a branch of the neuromodulation market. The company's focus on non-invasive treatments aligns with the growing trend of peripheral nerve stimulation, which is forecasted to grow significantly. Tivic Health's ClearUP product competes with over-the-counter pharmaceuticals and nasal irrigation products in the sinus pain and congestion treatment market.

Comparison to Industry Standards

• Tivic Health's ClearUP is the first FDA-approved bioelectronic treatment for sinus pain and congestion, representing a novel approach compared to traditional pharmaceutical and nasal irrigation treatments.
• The company's focus on non-invasive vagus nerve stimulation is an emerging area in bioelectronic medicine, with potential for improved efficacy and reliability compared to existing invasive and non-invasive VNS devices.
• Tivic Health's revenue and market share are small compared to established competitors in the over-the-counter sinus pain and congestion treatment market, such as GlaxoSmithKline, Bayer, Johnson & Johnson, NeilMed, and Rhinosystems Inc.
• The company's financial performance, including net losses and negative cash flows, is not uncommon for early-stage medical device companies, but it does raise concerns about its ability to continue as a going concern without additional funding.

Stakeholder Impact

• Shareholders: Potential dilution from the offering and future capital raises. Uncertainty regarding future profitability and stock price performance.
• Employees: Potential impact on job security if the company fails to achieve profitability or secure additional funding.
• Customers: Continued availability of ClearUP and potential introduction of new products.
• Suppliers: Potential impact from supply chain disruptions and changes in manufacturing partners.
• Creditors: Risk of default if the company is unable to meet its financial obligations.

Next Steps

• Complete the offering of common stock and warrants.
• Use the net proceeds for working capital, general corporate purposes, research and development, and potential acquisitions.
• Continue development of the vagus nerve stimulation platform.
• Conduct clinical trials for new product candidates.
• Seek regulatory approvals for new products.
• Expand sales and marketing efforts for ClearUP.
• Monitor and address supply chain constraints.
• Evaluate potential strategic acquisitions.

Key Dates

Keywords

bioelectronic medicine, neuromodulation, sinus pain relief, congestion relief, vagus nerve stimulation, medical device, healthcare technology, FDA approval, CE Mark, clinical trials, intellectual property, capital raise, working capital, direct-to-consumer sales, online retail, distribution agreements